公开(公告)号：US20240325380A1

公开(公告)日：2024-10-03

申请号：US18741475

申请日：2024-06-12

申请人： TMTRx, Inc.

发明人： Phillip R. Torralva

IPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

CPC分类号： A61K31/485 ,  A61K31/137 ,  A61K31/18 ,  A61K31/225 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/454 ,  A61K31/46 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/5517 ,  A61P25/36

摘要： Compositions are provided including a Mu opioid receptor antagonist, and an α2-adrenergic receptor agonist; or an α1 adrenergic receptor antagonist, together with one or more of a mu (or opioid receptor subtype) antagonist or agonist, (2) a vasopressor, (3) an anticholinergic agent and/or cholinergic agents, (4) a combined alpha-1 adrenergic antagonist and anticholinergic, (5) a paralytic or muscle relaxant, (6) a respiratory accelerant, (7) a GABA complex antagonist, (8) an anti-seizure/membrane stabilizer agent, (9) an α1 adrenergic receptor agonist, and/or (10) an α2 adrenergic receptor agonist; and a pharmaceutically acceptable carrier. Also provided are methods of preventing or reversing effects in a subject (including muscle and chest wall rigidity, laryngospasm, WCS, and/or respiratory depression) arising from intentional or accidental opioid or opiate exposure.

公开(公告)号：US20240287093A1

公开(公告)日：2024-08-29

申请号：US17268613

申请日：2019-08-21

申请人： ADLAI NORTYE BIOPHARMA CO., LTD.

发明人： Yufeng CHEN ,  Kaixuan CHEN ,  Pan LI ,  Canfeng LIU ,  Ji WANG ,  Qingchong QIU ,  Yang LU

IPC分类号： C07D498/06 ,  A61K31/4985 ,  A61K31/5383 ,  A61K31/5517 ,  A61K31/553 ,  A61K45/06 ,  C07D487/06

CPC分类号： C07D498/06 ,  A61K31/4985 ,  A61K31/5383 ,  A61K31/5517 ,  A61K31/553 ,  A61K45/06 ,  C07D487/06

摘要： The present disclosure provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using compounds of Formula (I) to prevent and/or treat immune-related disorders.

公开(公告)号：US20240287074A1

公开(公告)日：2024-08-29

申请号：US18044190

申请日：2021-09-07

申请人： Kinoxis Therapeutics Pty Ltd

发明人： Hugh ALSOP ,  Tristan REEKIE ,  Ronnie Maxwell LAWRENCE

IPC分类号： C07D487/04 ,  A61K31/5517 ,  A61P25/36

CPC分类号： C07D487/04 ,  A61K31/5517 ,  A61P25/36

摘要： This invention relates to solid forms of 1-methyl-1,4,5, IO-tetrahydropyrazolo[3,4-b][1,5]benzodiazepine freebase possessing desirable pharmacokinetic properties, such as low hygroscopicity and improved thermal stability. These solid forms include a crystalline form of 1-methyl-1,4,5,IO-tetrahydropyrazolo[3,4-b][1,5]benzodiazepine 5 freebase and phosphate and L-tartrate salts of 1-methyl-1,4,5,IO-tetrahydropyrazolo[3,4-b][1,5]benzodiazepine freebase. Pharmaceutical compositions, medicaments and kits comprising these solid forms are also described. Also provided are methods of using these forms to treat various diseases, conditions and disorders.

公开(公告)号：US12060427B2

公开(公告)日：2024-08-13

申请号：US17042013

申请日：2019-03-27

申请人： MITSUBISHI TANABE PHARMA CORPORATION

发明人： Julia Coronella ,  Marco Gymnopoulos ,  Vincent Blot ,  Ryo Fujita ,  Roland Newman

IPC分类号： C07K16/28 ,  A61K31/5517 ,  A61K39/00 ,  A61K47/64 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K31/5517 ,  A61K47/6415 ,  A61P35/00 ,  A61K2039/505

摘要： Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.

公开(公告)号：US20240216392A1

公开(公告)日：2024-07-04

申请号：US18524124

申请日：2023-11-30

申请人： Arena Pharmaceuticals, Inc.

发明人： Chadwick J. Orevillo ,  Randall Kaye ,  Nuggehally Srinivas

IPC分类号： A61K31/5517 ,  A61P25/08

CPC分类号： A61K31/5517 ,  A61P25/08

摘要： Provided herein are treatment methods including administering a 5-hydroxytryptamine (HT)2C receptor agonist to a patient in need thereof. An exemplary method includes treating or preventing a 5-hydroxytryptamine (HT)2C receptor-associated disorder in a patient in need thereof, wherein the method comprises administering to the patient (R)—N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (Compound 1), or a pharmaceutically acceptable salt thereof, wherein Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice daily.

公开(公告)号：US20240207428A1

公开(公告)日：2024-06-27

申请号：US18501451

申请日：2023-11-03

申请人： Magenta Therapeutics, Inc.

发明人： Andrew Nixon ,  Dwight Morrow ,  Adam Hartigan

IPC分类号： A61K47/68 ,  A61K31/4745 ,  A61K31/5517 ,  A61K31/704 ,  A61K35/12 ,  A61K35/28 ,  A61K38/07 ,  A61K38/12 ,  A61K39/00 ,  A61K39/395 ,  A61P35/02 ,  A61P37/06 ,  C07K14/37 ,  C07K16/28 ,  C12N5/00 ,  C12N5/0789

CPC分类号： A61K47/6817 ,  A61K31/4745 ,  A61K31/5517 ,  A61K31/704 ,  A61K35/12 ,  A61K35/28 ,  A61K38/07 ,  A61K38/12 ,  A61K39/395 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6811 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6897 ,  A61P35/02 ,  A61P37/06 ,  C07K14/37 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/289 ,  C07K16/2896 ,  C12N5/0087 ,  C12N5/0647 ,  A61K2035/124 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73 ,  C12N2501/599

摘要： The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

公开(公告)号：US20240207412A1

公开(公告)日：2024-06-27

申请号：US18196863

申请日：2023-05-12

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Thomas NITTOLI

IPC分类号： A61K47/54 ,  A61K31/395 ,  A61K31/5383 ,  A61K31/5517 ,  A61K38/07 ,  A61K38/17 ,  A61K47/55 ,  A61K47/65 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10 ,  A61P31/04 ,  A61P35/00

CPC分类号： A61K47/545 ,  A61K31/395 ,  A61K31/5383 ,  A61K31/5517 ,  A61K38/07 ,  A61K38/1729 ,  A61K47/542 ,  A61K47/55 ,  A61K47/65 ,  A61K47/6849 ,  A61K49/0052 ,  A61K49/0058 ,  A61K51/1093 ,  A61P31/04 ,  A61P35/00

摘要： Described herein are protein-payload conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic and/or imaging agent moieties. In certain embodiments, provided are specific and efficient methods for producing protein-payload constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and Diels-Alder techniques. Antibody-drug conjugates and compositions which comprise glutaminyl-modified antibodies, Diels-Alder adducts, and reactive payloads and are provided.

公开(公告)号：US20240207285A1

公开(公告)日：2024-06-27

申请号：US18390923

申请日：2023-12-20

申请人： Melt Pharmaceuticals, Inc.

发明人： Larry Dillaha

IPC分类号： A61K31/5517 ,  A61K9/00 ,  A61K31/135 ,  A61P25/20

CPC分类号： A61K31/5517 ,  A61K9/006 ,  A61K31/135 ,  A61P25/20

摘要： Provided herein are pharmaceutical compositions comprising midazolam and ketamine, and methods of inducing sedation (e.g., procedural sedation) in a subject using administration of such compositions, the compositions optionally including a pharmaceutically active compound of a third class. Compositions may be in sublingual or buccal form, or incorporated into vehicles for extended release. Methods for fabricating the compositions and using them for anesthesiological applications are also described.

公开(公告)号：US20240207243A1

公开(公告)日：2024-06-27

申请号：US18210625

申请日：2023-06-15

申请人： Eiger Biopharmaceuticals, Inc.

发明人： Richard Anthony FRANCO ,  Colin Michael HISLOP

IPC分类号： A61K31/4545 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/5517

CPC分类号： A61K31/4545 ,  A61K31/4439 ,  A61K31/451 ,  A61K31/5517

摘要： Methods of treating progeria, including HGPS and PL, are provided. In some embodiments, the method comprises administering to a subject having progeria a formulation of lonafarnib.

公开(公告)号：US20240180922A1

公开(公告)日：2024-06-06

申请号：US18437093

申请日：2024-02-08

申请人： University of Manitoba ,  University Health Network ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Paul Fernyhough ,  Nigel A. Calcutt ,  Lakshmi Kotra

IPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61K31/5517 ,  C07D417/12

CPC分类号： A61K31/5513 ,  A61K31/46 ,  A61K31/496 ,  A61K31/5517 ,  C07D417/12

摘要： Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.